Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Neuropace, Inc. on June 6, 2025. The meeting was conducted virtually via live webcast. The filing was signed on June 12, 2025, by Rebecca Kuhn, Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to corporate governance voting results.
Material Changes and Voting Results
Two proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors
- Joel Becker: Elected with 19,735,539 votes For, 120,448 Withheld, and 7,730,356 Broker Non-Votes.
- Frank Fischer: Elected with 14,717,455 votes For, 5,138,532 Withheld, and 7,730,356 Broker Non-Votes.
- Both directors were elected to serve until the 2028 Annual Meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- Stockholders ratified the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2025.
- Voting Results: 27,489,833 For, 90,789 Against, 5,721 Abstain, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced as being available in the definitive proxy statement filed on April 22, 2025.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Review the definitive proxy statement filed on April 22, 2025, for detailed background on the director nominees and the rationale for the auditor ratification.
- Note the significant number of Broker Non-Votes (7,730,356) on the director election, which may indicate shares held in street name where brokers lacked discretionary voting power.